Protocol Ledger

NCT03756103 · Phase II · COMPLETED

Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients

Interventional Phase II clinical trial protocol NCT03756103 sponsored by Shanghai Pharmaceuticals Holding Co in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-01-11 Enrollment: 120 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03756103
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03756103
Protocol FieldVerified Registry Value
NCT IdentifierNCT03756103
Consolidated Lead SponsorShanghai Pharmaceuticals Holding Co
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment120 participants (ACTUAL)
Registered Start Date2019-01-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI